Tempus to buy cancer test-maker Personalis for $1.5B
Dive Brief: Tempus AI said Monday it has agreed to buy Personalis for $1.5 billion. Fremont, California-based Personalis makes a molecular residual disease test for cancer. Tempus expects the acquisition…